Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 18;27(6):1071–1078. doi: 10.1038/s41591-021-01370-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Enrollment and follow-up of study participants vaccinated with 3.75 µg, 7.5 µg or 15 µg CoVLP with or without AS03 or CpG1018 adjuvant after the first and second dose administration. One participant in the 3.75 µg + AS03 treatment group did not receive the second vaccination as per protocol owing to a grade 3 AE (fatigue) after the first dose but agreed to have blood collection for immunogenicity. One participant in the 15 µg + CpG1018 treatment group withdrew consent before the second vaccination and consequently did not have blood collection at Day 21 and Day 42. Both participants were excluded from the per-protocol set. For more details of participant disposition, see Table 1. PP, per-protocol.